Faculty: Peter Ka-Fung Chiu, MD, Kae Jack Tay, MD and Arvin George, MD

Moderator: Ardeshir Rastinehad, MD and Tom Polascik, MD


Peter Ka-Fung Chiu, MD

Associate Professor
Division of Urology, Department of Surgery
Prince of Wales Hospital
The Chinese University of Hong Kong

MBChB (The Chinese University of Hong Kong)
PhD (Erasmus Medical Centre)
FRCSEd (Urol) (The College of Surgeons of Edinburgh)
FHKAM (Surg)

Dr. Peter Chiu graduated from the Faculty of Medicine of the Chinese University of Hong Kong and obtained the fellowship in Urology from the College of Surgeons of Edinburgh. He received post-graduate training on Prostate Cancer research and Andrology in the Erasmus Medical Centre in Rotterdam, The Netherlands, and obtained a PhD degree on Prostate Cancer diagnosis. The focus of his clinical practice and research is on Prostate cancer, from prostate cancer screening, diagnosis with novel biomarkers (prostate health index, urine spermine) and MRI-guided transperineal prostate biopsy, to focal therapy and Robotic surgery. He is currently the Honorary Secretary of the Hong Kong Urological Association, a member of the Prostate cancer working group of the EAU Young Academic Urologists, and a member of the SIU Academy Education council.

Kae Jack Tay, MD

Dr. Tay is a Director of Urologic Oncology and Senior Consultant Urologist at the Singapore General Hospital. He completed his urology residency at the Singapore General Hospital and his fellowship at Duke University, North Carolina, USA. Dr. Tay’s clinical practice includes focal therapy for prostate cancer, robotic pelvic surgery, complex resections of genitourinary (GU) cancers in the pelvis and retroperitoneum, and metastatic prostate cancer. He is an Assistant Professor at the Duke-NUS Graduate Medical School and is the Principal Investigator for a Phase II trial of Focal Cryotherapy for Prostate Cancer. He currently holds a National Medical Research Council, Singapore grant for risk stratification, advanced imaging, biopsy, active surveillance, and focal cryotherapy of prostate cancer.

Dr. Tay has published extensively on the topic of urologic cancer. He collaborates on several international multicenter projects including the Cryo On-Line Data (COLD) registry and the Shared Equal Access Regional Cancer Hospital (SEARCH) database. Dr. Tay has participated and lead several international expert consensuses on prostate focal therapy including the International Consultation of Urological Diseases (ICUD) consensus on follow-up surveillance after prostate focal therapy and an international consensus on Patient Selection for Prostate Focal Therapy.

Dr. Tay is a Board Member for the Focal Therapy Society and is presently the Chairman of its Website and Social Media Committee. He aims to develop better risk stratification methods for localized and metastatic prostate cancer and a modern approach to precision medicine in prostate cancer.

Arvin George, MD

Arvin George, MD is a Urologic Surgeon specializing in the diagnosis and management of genitourinary cancers.  After obtaining his medical degree from the Royal College of Surgeons in Ireland, he completed his Urology Residency at the Smith Institute for Urology, Hofstra North Shore-LIJ School of Medicine.  He remained to complete his Endourology fellowship in New York gaining additional subspecialty expertise in robotic, laparoscopic, and percutaneous surgery.  Subsequently, he completed a Urologic Oncology fellowship at the National Cancer Institute, National Institutes of Health.  Dr. George’s clinical practice includes both surgical and non-operative management of prostate, kidney, ureteral, testicular, and bladder cancers.  Dr. George’s research interests include minimally invasive and image-guided treatments, functional prostate imaging and focal therapy for prostate cancer. 

Ardeshir Rastinehad, MD

Northwell Health’s System Director for Prostate Cancer

Vice Chair at the Smith Institute for Urology at Lenox Hill

Dr. Art Rastinehad, D.O. initially joined the faculty at Northwell Health in 2011. Most recently, he was named Northwell Health’s System Director for Prostate Cancer at the Cancer Institute and the Vice Chair at the Smith Institute for Urology at Lenox Hill Hospital (January 2020). He has expertise in a wide array of interventional radiological and surgical techniques, including image guided procedures, prostate artery embolization, laparoscopic and robotic surgery. These hybrid skills were developed under the patience and kindness of his mentors Gopal Badlani (uro), Peter Choyke (rad), Louis Kavoussi (uro), Marston Linehan (uro), Igor Lobko (rad), Peter Pinto (uro), David N. Siegel (rad), Arthur Smith (uro), and Bradford Wood (rad).

Dr. Rastinehad has dedicated his career to research and education. As a medical student he was awarded a full-scholarship as a teaching fellow in anatomy for his last three years of medical school. During this time Dr. Rastinehad joined the research group at the North Shore/Long Island Jewish (NSLIJ) Department of Urology and the Division of Interventional Radiology. His early research on Selective Arterial Prostatic Embolization (SAPE) for patients with refractory hematuria secondary to radiation prostatitis laid the foundation for his multidisciplinary approach, subsequently completing a urology residency and interventional radiology fellowship at North Shore LIJ in 2009. Soon after, Dr. Rastinehad trained at the National Cancer Institute (2009-2011) as an Interventional Urologic Oncologist and is the first urologist to be dual fellowship trained in Urologic Oncology and Interventional Radiology.

Dr. Rastinehad has also authored and implemented several clinical trials of new techniques in the diagnosis and treatment of localized prostate cancer. In 2011 at Northwell Heath, he was the principal investigator for a Phase III clinical trial using MRI/Ultrasound fusion technology to improve prostate biopsy techniques and validated the original work from the NIH’s UOB/MIP/CIO programs. This was the first trial of this technology in the United States outside the National Institutes of Health. Dr. Rastinehad is considered one of the pioneers of this field, bringing prostate MRI and MR/US fusion guided prostate biopsy from the bench to clinical practice.

This new clinical approach is the groundwork for the evaluation of a new technique, Focal Therapy, which treats only the diseased portion of the prostate. While at the NIH, Dr. Rastinehad designed and authored the first trial assessing the utility of MR guided focal ablation of prostate tumors using MR US fusion biopsy data with Dr. Pinto as the PI (2010). As of May 2016, Dr Rastinehad was the first in the world to perform a gold nanoparticle directed ablation using a transperineal MR/US Fusion guided focal therapy system. This was the first-time nanoparticles were utilized to focally treat any cancer and this first series was recently published in Proceedings of the National Academy of Science (PNAS).

Dr Rastinehad is also one of the founding executive board members of the Focal Therapy Society (along with Drs. Polascik, De La Rosette, and Sanchez-Salas), which was started in October 2019 in collaboration with the Endourological Society. The society continues to grow and establish solid scientific principles to critically evaluate, disseminate, and perform focal therapy. In addition to his leadership role within the Focal Therapy Society, Dr. Rastinehad has been the course director and/or faculty for more than 30 courses nationally and internationally at the AUA, Endourological Society, Focal Therapy Society, and Société Internationale d'Urologie. Along with Dr. Pinto, he was the course director on the first use of MR/US fusion guided prostate biopsies in 2014. Continuing his goal to help bring these new treatments and approaches to the urologic community, he is currently developing the first Interventional Urology mobile platform combining image fusion, cone-beam CT/fluoroscopy, optical/EM tracking along with ESWL, ultrasound and the newest advances in radiation safety. These efforts will provide a platform for urologists to leverage these technologies and perform interventional treatments in their own operating rooms.